Aktis Oncology AKTS
NASDAQ AKTS
$16.62 +0.34 (+2.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Aktis Oncology (AKTS) Cash & Equivalents (2024 - 2026)

Updated

Aktis Oncology (AKTS) recorded Cash & Equivalents of $68.32 million in Q3 2026, down 17.2% from the prior quarter.

Analysis

Aktis Oncology (AKTS) Cash & Equivalents (2024 - 2026) Analysis & Trends

At the end of FY2025, Aktis Oncology reported Cash & Equivalents of $37.78 million, up 1.7% from FY2024.

  • Across earlier years, Cash & Equivalents came in at $37.16 million in FY2024.
  • Quarterly Cash & Equivalents has ranged from $37.16 million in Q4 2024 to $371.63 million in Q1 2026 over the past five years.
  • Per Business Quant, the preceding three quarters came in at $82.49 million (Q2 2026), $371.63 million (Q1 2026) and $37.78 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 4.89 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 16.91 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 10.77 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 9.55 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn - 400.00 Mn
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 7.94 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 13.19 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 6.44 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 1.82 Bn
10 Aktis Oncology 895.95 Mn 335.72 Mn - 68.32 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 68.32 Mn
Jun 30, 2026 82.49 Mn
Mar 31, 2026 371.63 Mn
Dec 31, 2025 37.78 Mn
Jun 30, 2025 110.22 Mn
Mar 31, 2025 58.25 Mn
Dec 31, 2024 37.16 Mn
API Access

Aktis Oncology Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AKTS&period=max&api_key=YOUR_API_KEY